

## **Supplementary Appendix**

### **Disease endpoints in FinnGen registries**

IPF in FinnGen was defined by having an ICD-10 J84.1 diagnosis. Endpoints for specific neoplasias were constructed by compiling the data from cancer registry (ICD-O-3), hospital discharge registry (ICD-8 to 10 codes), and causes of death registry (ICD-8 to 10 codes). We limit the scope of this study to the four common cancers having at least 2000 cases in FinnGen. “Any cancer” endpoint includes all malignant neoplasms (ICD-8 to 10, and ICD-O-3).

### **Array genotyping and imputation in FinnGen**

FinnGen participants were genotyped with Illumina and Affymetrix arrays (Illumina Inc., San Diego, and Thermo Fisher Scientific, Santa Clara, CA, USA), and genotype calls were made with the GenCall or zCall (for Illumina) and the AxiomGT1 algorithm for Affymetrix data.

Participants with ambiguous gender, high genotype missingness (>5%), excess heterozygosity (+4SD) and non-Finnish ancestry were excluded; as well as all variants with high missingness (>2%), low HWE P-value (<1e-6) and minor allele count (MAC<3). Array data pre-phasing was carried out with Eagle 2.3.511 with the number of conditioning haplotypes set to 20,000.

Genotype imputation was done with Beagle 4.1,<sup>1,2</sup> (described in <https://dx.doi.org/10.17504/protocols.io.xbgfijw>) by using the SISu v3 population specific reference panel developed from high-quality data for 3,775 high-coverage (25-30x) WGS in Finns.

### **Longitudinal analysis in FinnGen**

National registers cover the whole health history of study participants regardless of the age of study enrollment. To examine prevalence prior to joining the study, we followed participants from their birth till the age of study enrollment, IPF, or any cancer, whichever occurred first. To model incidence, we left-truncated the data at the age of study entry, i.e. followed participants from the age of study enrollment till IPF, any cancer, death, or end of the study follow-up, and excluded all participants with prevalent cancer or IPF prior to joining the study. In the combined analysis, we included all individuals at their birth and followed them to the end of the study follow-up or first event of interest, without considering the study recruitment time. We used age as the time-scale in all disease onset models. In contrast to case-control GWAS, participants with other cancer were not excluded but censored at the age of the first competing risk event to model cause-specific hazards.

Both genetic principal component covariates manifested non-linearity with any cancer onset ( $p < 2e-16$ ), and were thus included as penalized smoothing splines into all models. Proportional hazards assumption was evaluated using Schoenfeld residuals and respective proportional hazard tests in each model. After accounting for multiple testing, the first genomic principal component showed non-proportionality in respect to any cancer onset among prevalent cases ( $p = 0.002$ ). Consequently, we included both principal components as time-dependent covariates to all models for consistency.

Cumulative incidence functions were estimated with Aalen-Johansen estimators to account for competing risks of IPF, any cancer, and death without cancer. Illustrations of cumulative incidence are graphically smoothed to retain anonymity of study participants where appropriate.

All longitudinal statistical analyses were done using *R-4.0.3* and package *survival*.

### **Calling somatic variants from array intensity data in FinnGen**

The genotype and intensity data was processed with the apt-probeset-genotype tool (<http://www.affymetrix.com/support/developer/powertools/changelog/apt-probeset-genotype.html>) and used to call mosaic chromosomal alterations (mCA) in 153,548 FinnGen (Release V) participants genotyped with FinnGen ThermoFisher Axiom custom array version 1 or 2. The calling was performed using the “txt” mode of the MoChA WDL pipeline (<https://github.com/freeseek/mocha>) that includes (i) converting intensity data to VCF files with B Allele Frequency (BAF) and Log R Ratio (LRR) using the *gtc2vcf* tool (<https://github.com/freeseek/gtc2vcf>), (ii) phasing the full cohort using the SHAPEIT4 software,<sup>1</sup> and (iii) calling mCA by detecting allelic imbalance of heterozygous sites based on LRR and phased BAF.

Participants with poor genotyping quality (185 participants with possible DNA contamination and 83 participants with discordance in phenotype-genotype sex) and event calls likely to be constitutional duplications or deletions were filtered using the criteria suggested by the MoChA pipeline. After further removing 1st and 2nd-degree relatives, a total of 148,272 participants were left for further analyses.

We analyzed mCa from autosomes and sex chromosomes separately.<sup>3</sup> Given MoChA was designed to search for allelic imbalance in heterozygous sites, only pseudoautosomal regions (PAR1 and PAR2) were analyzed for men by ignoring all non-PAR regions and then defining any mosaic events as mosaic Y rather than mosaic X. Thus, mosaic X is only defined for women and mosaic Y only for men. Given the most common mCa types in sex chromosomes are loss events for mLOY and mLOX,<sup>4,5</sup> we further defined two additional mCA subtypes specific for loss events based on the length of mCA events: (i) the mosaic loss of Y for mCA longer than 1Mb and (ii) the mosaic loss of X for mCA longer than 50 Mb.

### **Telomere length analysis in the Northern Finland Birth Cohort and Finnish Twin Cohort**

The Northern Finland Birth Cohort 1966 (NFBC1966) is a prospective birth cohort study that recruited all pregnant women living in the Oulu and Lapland provinces of Finland with expected delivery in 1966, comprising in total 12,231 children and their parents with follow-ups at 1, 14, 31, and 46 years of age (University of Oulu 1966). All participants included in the study are from Finnish ancestry and are independent from the FinnGen sample. Mean relative leukocyte telomere length (LTL) was measured using monochrome multiplex qPCR method at 31-year follow-up. LTL at 46-year follow-up was measured in triplicates using albumin as a single-copy gene reference. The associations with genetic variants were assessed after a rank-based inverse normal transformation of LTL among 4,961 (48.4% males) and 3,547 (43.9% males) individuals at 31 and 46 years respectively.

Relative telomere length in the Finnish Twin Cohort (FTC) was measured with qPCR at the age of DNA collection among adult twins from three substudies: (i) the Nicotine Addiction Genetics study, (ii) the Finnish Twin Study on Ageing, and (iii) the TwinFat study.<sup>6,7</sup> The association of genetic variants and normalized logarithm of LTL was assessed using a linear mixed-model adjusted with age and sex, and by including family-identifier as a random effect to account for within-pair dependency.


## Supplementary Results

### IPF-GWAS in FinnGen


In addition to *SPDL1* and *TERT* variants, we identified two additional novel loci (at *TACC2* and *AXINI*) at  $P < 5 \times 10^{-8}$  in FinnGen. The identified *TACC2* locus at 10q26.13 included a single credible set where the most probable causal allele (rs967235139 causal probability 36.7%, MAF 0.21%, odds ratio for the C allele, 35.86; 95% CI 9.96 to 129.05;  $P = 4.30 \times 10^{-8}$ ) is only polymorphic in the Finnish population according to the GnomAD resource,<sup>8</sup> and hence could not be replicated in the IPF meta-analysis with participants of non-Finnish European ancestry and considering only variants with MAF  $> 1\%$ .

Also the *AXINI* locus at 16p13.3 included a single credible set for the locus (rs185488877 causal probability 32.5%, MAF 1.89%, odds ratio for the T allele, 2.74; 95% CI 1.93 to 3.91;  $P = 2.32 \times 10^{-8}$ ) is rarely seen polymorphic in other than Finnish population as MAF in non-Finnish Europeans in gnomAD is 0.31% and the variant was not available in the IPF meta-analysis summary statistics. Axin1/2 have been previously described as cancer associated but also with Wnt-signaling,<sup>9</sup> relevant to fibrotic processes.

A Manhattan plot for test statistics from the FinnGen IPF is depicted in Supplementary Figure S1, in addition to quantile-quantile plot of observed and expected test statistics in Supplementary Figure S2. An overall genomic inflation factor ( $\lambda_{GC}$ ) of 1.0311 was noted.



Supplementary Figure S1. Manhattan plot of the FinnGen IPF GWAS statistics. The dash line indicates the genome-wide significance threshold of a P value less than  $5 \times 10^{-8}$ .



Supplementary Figure S2. Quantile-quantile plot of Observed and Expected test statistics in equally sized variant frequency bins in the FinnGen IPF GWAS.

## Effects of *SPDL1* missense variant in FinnGen

The potential pleiotropic effects of *SPDL1* missense variant (rs116483731) was assessed across FinnGen endpoints (n=2,925) and depicted in the table S1. Effects beyond  $P < 1 \times 10^{-5}$  were only seen in IPF, closely related pulmonary phenotypes. and different malignancy-related phenotypes.

Endpoint	OR	P
Idiopathic pulmonary fibrosis	3.13	9.97E-16
Malignant neoplasm	0.81	2.05E-15
ILD, hospital admissions 1, main diag only	2.25	4.48E-14
Other respiratory diseases principally affecting the interstitium	1.95	1.43E-13
Interstitial lung disease	2.09	2.10E-13
Other interstitial pulmonary diseases	2.06	4.03E-13
ILD, hospital admissions	2.08	4.44E-13
Respiratory diseases principally affecting the interstitium, IBD co-morbidities	1.88	8.07E-11
Malignant neoplasm of prostate (all cancers excluded)	0.69	1.82E-08
Malignant neoplasm of skin (all cancers excluded)	0.77	2.10E-08
Other malignant neoplasms of skin (=non-melanoma skin cancer) (all cancers excluded)	0.77	2.23E-08
malignant neoplasm of male genital organs (all cancers excluded)	0.70	2.23E-08
Malignant neoplasm of prostate	0.72	2.37E-07
ILD, hospital admission 2, with pulmonary infections	1.91	2.83E-07
malignant neoplasm of male genital organs	0.73	3.26E-07
Interstitial lung disease endpoints	1.17	9.16E-07
Malignant neoplasm of skin	0.80	1.37E-06
Other malignant neoplasms of skin (=non-melanoma skin cancer)	0.80	1.41E-06
ILD, hospital admissions 3, with pneumonia sepsis	1.93	1.9E-06
Malignant neoplasm of breast (all cancers excluded)	0.79	7.15E-06

Supplementary Table S1. Disease and health related endpoint associations of *SPDL1* missense variant rs116483731 alternative allele A in FinnGen with  $P < 1 \times 10^{-5}$ .

## Effects of other *SPDL1* functional variation in FinnGen

Altogether 13 predicted coding variants were seen in the *SPDL1* gene in FinnGen. Coding variation beyond rs116483731 was assessed within the scope of FinnGen endpoints, Supplementary Table S2. No other predicted functional variant associated with disease endpoints at  $P < 1 \times 10^{-5}$ .

Variant	Ref/Alt	AF <sub>alt</sub>	INFO	Predicted effect
rs3797713	T/C	0.67	1.00	Missense
rs3777084	T/C	0.67	1.00	Missense
rs140884129	G/A	2.80E-03	0.99	Missense
rs199675882	A/G	3.30E-03	1.00	Missense
rs146344218	C/T	2.20E-03	0.96	Missense
rs140005442	A/G	8.00E-04	0.99	Splice acceptor
rs144297297	G/A	4.40E-04	0.95	Missense
rs143453400	A/T	1.30E-03	0.95	Missense
rs78480498	C/A	9.40E-03	0.99	Missense
rs140080951	G/A	6.10E-03	0.99	Missense
rs147788748	C/T	6.40E-04	0.97	Missense
rs144151613	A/T	1.30E-03	0.97	Missense

Supplementary Table S2. Functional variation and associated disease endpoints ( $P < 1 \times 10^{-4}$ ) in FinnGen.

### ***SPDL1* missense variant and the risk of IPF and cancer in FinnGen**

To further assess the risk-increasing effect of rs116483731 in IPF and decreasing effect in cancer subtypes, we analyzed the FinnGen data with cause-specific Cox proportional hazards models separating participants by the disease status at study entry, referred as incident, prevalent and as a combination of both (Supplementary Table S3), and by considering other cancer and IPF as competing risk events.

Disease	Prevalent and incident		Prevalent only		Incident only	
	HR (95% CI)	p	HR (95% CI)	p	HR (95% CI)	p
Colorectal cancer	0.93 (0.79-1.11)	0.44	0.87 (0.70-1.09)	0.23	1.05 (0.80-1.38)	0.74
Prostate cancer	0.71 (0.62-0.81)	6.11e-07	0.74 (0.62-0.87)	2.62e-04	0.67 (0.53-0.84)	4.67e-04
Breast cancer	0.81 (0.73-0.90)	5.55e-05	0.80 (0.71-0.90)	3.01e-04	0.84 (0.69-1.01)	0.07
Nonmelanoma skin cancer	0.82 (0.75-0.90)	4.16e-05	0.79 (0.71-0.89)	8.62e-05	0.88 (0.75-1.03)	0.12
Any cancer	0.83 (0.79-0.87)	4.23e-15	0.83 (0.79-0.88)	1.52e-10	0.83 (0.76-0.90)	5.59e-06
IPF	2.27 (1.86-2.76)	4.46e-16	2.52 (1.98-3.22)	1.08e-13	1.88 (1.35-2.64)	2.22e-04

Supplementary Table S3. Hazard ratios in IPF, cancer, and subtypes from cause-specific Cox proportional hazards models for the *SPDL1* missense variant rs116483731 allele A in FinnGen.

### **Association of *SPDL1* and *TERT* variants with telomere length in NFBC1966 and FTC**

The association of three identified functional variants in *SPDL1* and *TERT* on Lymphocyte Telomere Length (LTL) was analyzed in the independent NFBC1966 study at the age of 31 and 46. We saw no effect for the *SPDL1* missense variant rs116483731, while association was observed for both of the *TERT* alleles rs770066110 and rs776981958 in NFBC1966 (Supplementary Table S4). The effect of both *TERT* variants was confirmed in the FTC study (Supplementary Table S5). A large LTL meta-analysis<sup>10</sup> further supports our notion that the *SPDL1* missense variant seems to have no effect on the LTL (rs116483731 allele A,  $\beta = 0.0099$ ,  $P = 0.21$ ).

Variant	Ref/Alt	LTL Age	Beta <sub>alt</sub> (95% CI)	P
rs770066110	G/A	31	-0.66 (-0.57 – -0.10)	0.021
rs776981958	T/C	31	-0.90 (-0.49 – -0.41)	3.39E-04
rs116483731	G/A	31	0.03 (-0.11 – 0.14)	0.62
rs770066110	G/A	46	-0.79 (-0.65 – -0.14)	0.017
rs776981958	T/C	46	-1.00 (-0.62 – -0.38)	1.59E-03
rs116483731	G/A	46	0.02 (-0.13 – 0.14)	0.81

**Supplementary Table S4. Effect of *SPDL1* and *TERT* functional variants Lymphocyte Telomere Length (LTL) in the independent NFBC1966 study, measured at the age of 31yrs and 46yrs.** Linear regression of carrier status and normalized LTL (rank-based inverse normal transformation).

Variant	Ref/Alt	Beta <sub>alt</sub> (95% CI)	P
rs770066110	G/A	-2.41 (-3.86 – -0.96)	1.17E-03
rs776981958	T/C	-0.90 (-1.66 – -0.15)	0.019

**Supplementary Table S5. Effect of *SPDL1* and *TERT* functional variants Lymphocyte Telomere Length (LTL) in FTC study, measured at the time of DNA collection in each substudy.** Linear mixed-model regression of carrier status and normalized logarithm of LTL, models were adjusted with age and sex where within-pair dependency was accounted for by using family-identifier as a random effect.

### ***TERT* variants and the risk of IPF and cancer in FinnGen**


We confirmed the increasing effect for IPF-risk and the decreasing effect for any cancer of the two functional *TERT* mutations (Supplementary Table S6). In addition, a protective effect against prostate cancer was observed.

Disease	Prevalent and incident		Prevalent only		Incident only	
	HR (95% CI)	p	HR (95% CI)	p	HR (95% CI)	p
Colorectal cancer	0.88 (0.44-1.76)	0.72	-	-	-	-
Prostate cancer	0.28 (0.12-0.67)	4.25e-3	-	-	-	-
Breast cancer	0.99 (0.69-1.40)	0.94	0.98 (0.64-1.50)	0.92	1.02 (0.55-1.9)	0.96
Nonmelanoma skin cancer	0.80 (0.56-1.17)	0.25	0.77 (0.49-1.23)	0.28	0.86 (0.46-1.61)	0.64
Any cancer	0.78 (0.65-0.94)	8.36e-3	0.76 (0.60-0.95)	0.02	0.84 (0.62-1.14)	0.25
IPF	13.9 (10.3-18.8)	3.00e-65	14.1 (9.59-20.7)	1.34e-41	13.8 (8.41-22.5)	1.68e-25

Supplementary Table S6. Hazard ratios of IPF, cancer, and subtypes from cause-specific Cox proportional hazards models in carriers of either of *TERT* functional mutations. Instances with less than five mutation-carrying cases were left out from the analysis.

### **Mosaic Chromosomal Alterations in FinnGen**

Most of the mCA events were seen in the sex chromosomes and autosomal events accounted for 25.6% of all mCAs in women and 13.5% in men (Supplementary Table S7, Supplementary Fig. S3), consistent with previous reports.<sup>11</sup> The mosaic deletion in chromosome Y, usually termed as mosaic loss of chromosome Y (mLOY), was the most common form of clonal mosaicism observed. Among the 10,309 mCA events observed in chromosome Y with distinguishable types, 91.8% were classified as mLOY (Supplementary Table S7). Odds ratios of six variants associated with both IPF and cancer with their effects on the incidence of mCA events in FinnGen are illustrated in the Supplementary Table S8.



Supplementary Figure S3. Prevalence of mosaic chromosomal alteration (mCA) by 5-year age bins in male and female FinnGen participants (a subset with intensity data available, n=148,272).

Mosaic Chromosomal Alteration	Women	Men	Total (%)
Any chromosome	6,519	11,498	<b>18,017 (48 %)</b>
Autosomal	1,430	1,516	<b>2,946 (7.9 %)</b>
Chromosome X	5,309	0	<b>5,309 (14 %)</b>
Chromosome Y	0	10,449	<b>10,449 (28 %)</b>
Autosomal and ChrX	220	0	<b>220 (0.59 %)</b>
Autosomal and ChrY	0	467	<b>467 (1.2 %)</b>
<b>Total (%)</b>	<b>13,478 (36 %)</b>	<b>23,930 (64 %)</b>	<b>37,408 (100 %)</b>

Supplementary Table S7. Number mCA carriers in FinnGen by sex (in a subset with intensity data available, n=148,272).

Mosaic Chromosomal Alteration	Rsid	Gene	Ref/Alt	OR <sub>inc</sub> (95% CI)	P
AnyChr	rs2293607	TERC-ACRT3	T/C	1.00 (0.96 - 1.04)	0.88
AnyChr	rs116483731	SPDL1	G/A	0.71 (0.63 - 0.79)	5.36E-09
AnyChr	rs10950456	MAD1L1	G/A	0.94 (0.90 - 0.97)	6.42E-04
AnyChr	rs7902587	OBFC1	C/T	0.96 (0.90 - 1.02)	0.22
AnyChr	rs112064988	MAP2K1	C/T	1.03 (0.99 - 1.08)	0.12
AnyChr	rs75691080	RTEL1-STMN3	C/T	0.97 (0.91 - 1.02)	0.21
Autosomes	rs2293607	TERC-ACRT3	T/C	0.98 (0.90 - 1.08)	0.71
Autosomes	rs116483731	SPDL1	G/A	0.88 (0.68 - 1.11)	0.3
Autosomes	rs10950456	MAD1L1	G/A	0.90 (0.82 - 0.97)	8.10E-03
Autosomes	rs7902587	OBFC1	C/T	1.05 (0.91 - 1.21)	0.46
Autosomes	rs112064988	MAP2K1	C/T	0.99 (0.90 - 1.09)	0.83
Autosomes	rs75691080	RTEL1-STMN3	C/T	0.94 (0.83 - 1.07)	0.34
Large_AnyChr	rs2293607	TERC-ACRT3	T/C	1.02 (0.96 - 1.09)	0.47
Large_AnyChr	rs116483731	SPDL1	G/A	0.71 (0.59 - 0.84)	9.77E-05
Large_AnyChr	rs10950456	MAD1L1	G/A	0.94 (0.88 - 0.99)	1.74E-02
Large_AnyChr	rs7902587	OBFC1	C/T	0.92 (0.83 - 1.01)	0.08
Large_AnyChr	rs112064988	MAP2K1	C/T	1.06 (0.99 - 1.12)	0.08
Large_AnyChr	rs75691080	RTEL1-STMN3	C/T	0.97 (0.89 - 1.05)	0.47
Large_Autosomes	rs2293607	TERC-ACRT3	T/C	0.97 (0.86 - 1.10)	0.63
Large_Autosomes	rs116483731	SPDL1	G/A	0.98 (0.70 - 1.34)	0.92
Large_Autosomes	rs10950456	MAD1L1	G/A	0.93 (0.83 - 1.05)	0.23
Large_Autosomes	rs7902587	OBFC1	C/T	0.99 (0.81 - 1.20)	0.94
Large_Autosomes	rs112064988	MAP2K1	C/T	1.00 (0.88 - 1.13)	0.99
Large_Autosomes	rs75691080	RTEL1-STMN3	C/T	0.79 (0.65 - 0.94)	1.15E-02
ChrY	rs2293607	TERC-ACRT3	T/C	1.02 (0.96 - 1.07)	0.6
ChrY	rs116483731	SPDL1	G/A	0.65 (0.55 - 0.76)	1.27E-07
ChrY	rs10950456	MAD1L1	G/A	0.91 (0.87 - 0.96)	5.63E-04
ChrY	rs7902587	OBFC1	C/T	0.92 (0.84 - 1.01)	0.07
ChrY	rs112064988	MAP2K1	C/T	1.07 (1.01 - 1.13)	2.56E-02
ChrY	rs75691080	RTEL1-STMN3	C/T	0.97 (0.90 - 1.05)	0.49
Large_ChrY	rs2293607	TERC-ACRT3	T/C	1.03 (0.96 - 1.10)	0.41
Large_ChrY	rs116483731	SPDL1	G/A	0.64 (0.52 - 0.78)	2.52E-05
Large_ChrY	rs10950456	MAD1L1	G/A	0.93 (0.87 - 0.99)	2.21E-02
Large_ChrY	rs7902587	OBFC1	C/T	0.88 (0.79 - 0.99)	2.99E-02
Large_ChrY	rs112064988	MAP2K1	C/T	1.10 (1.03 - 1.18)	7.50E-03
Large_ChrY	rs75691080	RTEL1-STMN3	C/T	1.02 (0.93 - 1.12)	0.67
LOY	rs2293607	TERC-ACRT3	T/C	1.02 (0.96 - 1.07)	0.58
LOY	rs116483731	SPDL1	G/A	0.65 (0.55 - 0.76)	1.37E-07
LOY	rs10950456	MAD1L1	G/A	0.91 (0.87 - 0.96)	4.80E-04
LOY	rs7902587	OBFC1	C/T	0.92 (0.84 - 1.01)	0.07
LOY	rs112064988	MAP2K1	C/T	1.07 (1.01 - 1.13)	2.56E-02
LOY	rs75691080	RTEL1-STMN3	C/T	0.97 (0.90 - 1.05)	0.49
Large_LOY	rs2293607	TERC-ACRT3	T/C	1.03 (0.96 - 1.11)	0.38
Large_LOY	rs116483731	SPDL1	G/A	0.64 (0.52 - 0.79)	2.74E-05
Large_LOY	rs10950456	MAD1L1	G/A	0.93 (0.87 - 0.99)	1.88E-02
Large_LOY	rs7902587	OBFC1	C/T	0.88 (0.79 - 0.99)	3.29E-02
Large_LOY	rs112064988	MAP2K1	C/T	1.10 (1.03 - 1.18)	7.35E-03
Large_LOY	rs75691080	RTEL1-STMN3	C/T	1.02 (0.93 - 1.12)	0.67
ChrX	rs2293607	TERC-ACRT3	T/C	0.99 (0.93 - 1.06)	0.83
ChrX	rs116483731	SPDL1	G/A	0.68 (0.55 - 0.83)	2.06E-04
ChrX	rs10950456	MAD1L1	G/A	0.98 (0.92 - 1.04)	0.44
ChrX	rs7902587	OBFC1	C/T	0.97 (0.86 - 1.08)	0.52
ChrX	rs112064988	MAP2K1	C/T	1.02 (0.95 - 1.09)	0.56
ChrX	rs75691080	RTEL1-STMN3	C/T	0.96 (0.87 - 1.05)	0.38
Large_ChrX	rs2293607	TERC-ACRT3	T/C	1.08 (0.85 - 1.36)	0.55
Large_ChrX	rs116483731	SPDL1	G/A	0.55 (0.22 - 1.12)	0.14
Large_ChrX	rs10950456	MAD1L1	G/A	0.93 (0.75 - 1.16)	0.49
Large_ChrX	rs7902587	OBFC1	C/T	1.01 (0.67 - 1.45)	0.97
Large_ChrX	rs112064988	MAP2K1	C/T	0.76 (0.58 - 0.99)	4.34E-02
Large_ChrX	rs75691080	RTEL1-STMN3	C/T	0.87 (0.60 - 1.22)	0.43
LOX	rs2293607	TERC-ACRT3	T/C	1.00 (0.93 - 1.07)	0.88
LOX	rs116483731	SPDL1	G/A	0.67 (0.54 - 0.82)	1.88E-04
LOX	rs10950456	MAD1L1	G/A	0.97 (0.91 - 1.04)	0.42
LOX	rs7902587	OBFC1	C/T	0.96 (0.86 - 1.07)	0.47
LOX	rs112064988	MAP2K1	C/T	1.03 (0.96 - 1.11)	0.39
LOX	rs75691080	RTEL1-STMN3	C/T	0.96 (0.87 - 1.06)	0.42
Large_LOX	rs2293607	TERC-ACRT3	T/C	1.21 (0.89 - 1.62)	0.22
Large_LOX	rs116483731	SPDL1	G/A	0.15 (0.01 - 0.67)	0.06
Large_LOX	rs10950456	MAD1L1	G/A	0.98 (0.74 - 1.31)	0.88
Large_LOX	rs7902587	OBFC1	C/T	0.95 (0.56 - 1.52)	0.84
Large_LOX	rs112064988	MAP2K1	C/T	0.78 (0.55 - 1.08)	0.14
Large_LOX	rs75691080	RTEL1-STMN3	C/T	0.93 (0.58 - 1.41)	0.75

Supplementary Table S8. Odds ratios of 6 variants found to be associated with both IPF and cancer, with their effects on the incidence of different mCA events in FinnGen participants. A logistic regression adjusted with age, age<sup>2</sup>, sex and ever-smoking status (in a subset with intensity data and smoking status available, n=73.339)

## SPDL1 expression in TCGA




We compared the expression of *SPDL1* between normal and tumor samples in the TCGA data <sup>12</sup>. The results shown here are in whole or in part based upon data generated by the TCGA Research Network (<https://www.cancer.gov/tcga>). Altogether 11 cancer types having RNA-sequencing data from at least 20 normal tissue samples were included in the analysis: Breast invasive carcinoma (BRCA), Head and Neck squamous cell carcinoma (HNSC), Kidney Chromophobe (KICH), Kidney renal clear cell carcinoma (KIRC), Kidney renal papillary cell carcinoma (KIRP), Liver hepatocellular carcinoma (LIHC), Lung adenocarcinoma (LUAD), Lung squamous cell carcinoma (LUSC), Prostate adenocarcinoma (PRAD), Stomach adenocarcinoma (STAD), and Thyroid carcinoma (THCA) (Supplementary Table S9).

Cancer Type	Normal Sample Count	Tumor Sample Count	P
Breast invasive carcinoma (BRCA)	112	112	3.9e-13
Head and Neck squamous cell carcinoma (HNSC)	43	43	7.71e-03
Kidney Chromophobe (KICH)	25	25	1.28e-01
Kidney renal clear cell carcinoma (KIRC)	72	72	1.97e-07
Kidney renal papillary cell carcinoma (KIRP)	32	32	6.66e-04
Liver hepatocellular carcinoma (LIHC)	50	50	4.13e-08
Lung adenocarcinoma (LUAD)	58	58	8.69e-10
Lung squamous cell carcinoma (LUSC)	51	51	3.58e-10
Prostate adenocarcinoma (PRAD)	52	52	2.4e-03
Stomach adenocarcinoma (STAD)	32	32	1.49e-06
Thyroid carcinoma (THCA)	59	59	2.49e-01

Supplementary Table S9. Comparison of Normalized *SPDL1* expression in TCGA tumors and normal samples.

Cancer cohorts were subsampled to keep the same individuals in normal and tumor groups and a t-test was used to compare normalized gene expression levels between the two tissue source sites for each cancer type (Supplementary Fig. S4). Out of tested cancer types, 9 demonstrated significantly higher expression of *SPDL1* in tumors rather than in normal tissue samples (at threshold  $p < 4 \cdot 5 \times 10^{-3}$ ).



Supplementary Figure S4. Normalized *SPDL1* expression in TCGA tumors and normal samples.

### Overlap of IPF meta-analysis with FinnGen and UKB pan-cancer analysis

Leading 62 SNVs from the FinnGen and UKB pan-cancer analysis and their overlap with the latest IPF meta-analysis (Allen et al. 2020) is illustrated in the Supplementary Table S10.

Variant	Gene	Ref/Alt	OR <sub>Alt</sub> (95% CI)			P			
			FinnGen Any cancer	UKBB Any cancer	Allen et al. (2020) IPF	FinnGen	UKBB	FinnGen & UKBB	Allen et al. (2020)
rs2293607	ACTRT3	T/C	0.95 (0.94 - 0.97)	0.96 (0.95 - 0.98)	1.29 (1.20 - 1.39)	1.50E-07	1.95E-07	1.80E-13	2.33E-11
rs10950456	MAD1L1	G/A	0.97 (0.96 - 0.99)	0.97 (0.96 - 0.98)	1.20 (1.12 - 1.28)	6.45E-04	4.41E-07	1.20E-09	1.19E-07
rs116483731	SPDL1	G/A	0.79 (0.76 - 0.83)	0.89 (0.83 - 0.96)	2.40 (1.70 - 3.40)	1.08E-22	0.00121	2.10E-23	7.55E-07
rs7902587	OBFC1	C/T	1.05 (1.02 - 1.08)	1.08 (1.06 - 1.11)	0.76 (0.68 - 0.85)	7.13E-04	1.54E-13	2.22E-15	2.08E-06
rs75691080	STMN3	C/T	0.92 (0.9 - 0.94)	0.94 (0.92 - 0.96)	1.30 (1.16 - 1.46)	8.68E-12	3.16E-07	5.23E-17	4.29E-06
rs112064988	MAP2K1	C/T	1.03 (1.01 - 1.05)	1.03 (1.02 - 1.05)	0.87 (0.81 - 0.94)	4.39E-04	1.26E-05	2.08E-08	6.77E-04
rs17599629	CERS2	A/G	1.05 (1.03 - 1.07)	1.04 (1.03 - 1.06)	1.14 (1.05 - 1.23)	4.55E-06	1.53E-08	3.35E-13	1.32E-03
rs3818625	SMC2	G/A	1.04 (1.02 - 1.06)	1.03 (1.02 - 1.04)	1.09 (1.02 - 1.16)	6.92E-07	4.51E-06	2.43E-11	0.01
rs12203592	IRF4	C/T	1.12 (1.07 - 1.17)	1.13 (1.11 - 1.15)	1.09 (1.00 - 1.19)	1.01E-06	3.71E-55	2.51E-60	0.04
rs78378222	TP53	T/G	1.24 (1.17 - 1.32)	1.25 (1.18 - 1.33)	0.71 (0.52 - 0.98)	1.40E-12	9.84E-15	9.67E-26	0.04
rs801108	RP4-799G3.2	C/G	1.04 (1.02 - 1.06)	1.07 (1.05 - 1.08)	1.08 (1.00 - 1.17)	9.90E-06	1.22E-18	7.76E-22	0.04
rs11611584	KRT5	C/A	1.04 (1.02 - 1.07)	1.06 (1.04 - 1.08)	0.89 (0.80 - 1.00)	6.47E-04	1.07E-07	5.10E-10	0.05
rs37004	N/A	C/T	0.96 (0.95 - 0.98)	0.96 (0.94 - 0.97)	1.07 (0.99 - 1.16)	6.61E-05	1.76E-09	6.12E-13	0.08
rs2384054	N/A	T/C	0.97 (0.95 - 0.98)	0.98 (0.96 - 0.99)	1.06 (0.99 - 1.13)	2.54E-05	0.000249	4.01E-08	0.09
rs6059655	RALY	A/G	0.95 (0.90 - 1.00)	0.89 (0.87 - 0.91)	0.91 (0.81 - 1.02)	3.68E-02	3.33E-28	3.98E-28	0.10
rs148297846	TERT	G/A	1.06 (1.02 - 1.11)	1.07 (1.05 - 1.09)	0.91 (0.80 - 1.03)	7.05E-03	6.17E-09	1.51E-10	0.12
rs17879961	CHEK2	A/G	1.17 (1.12 - 1.23)	1.49 (1.08 - 2.06)	0.56 (0.26 - 1.24)	2.99E-12	0.0155	4.40E-13	0.15
rs7028268	CDKN2B-AS1	G/A	0.96 (0.94 - 0.97)	0.96 (0.94 - 0.97)	0.95 (0.89 - 1.02)	1.92E-08	1.93E-11	2.09E-18	0.16
rs28792460	RGS22	A/G	0.94 (0.92 - 0.96)	0.95 (0.94 - 0.97)	1.06 (0.97 - 1.16)	1.85E-11	4.46E-08	9.08E-18	0.19
rs340797	N/A	G/T	0.97 (0.94 - 1.00)	0.95 (0.93 - 0.96)	0.93 (0.84 - 1.04)	3.02E-02	5.54E-08	1.04E-08	0.21
rs72928038	BACH2	G/A	0.96 (0.94 - 0.98)	0.95 (0.94 - 0.97)	0.95 (0.87 - 1.03)	5.61E-04	1.04E-08	2.44E-11	0.24
rs8037137	PRC1	T/C	0.94 (0.92 - 0.96)	0.96 (0.94 - 0.98)	1.05 (0.96 - 1.16)	2.81E-09	3.82E-06	1.52E-13	0.28
rs13316357	FOXP1	A/G	1.04 (1.02 - 1.06)	1.04 (1.02 - 1.05)	0.96 (0.90 - 1.03)	6.08E-06	1.20E-07	3.41E-12	0.29
rs157936	KLF14, MIR29A	T/G	0.97 (0.96 - 0.99)	0.96 (0.95 - 0.98)	0.96 (0.90 - 1.03)	2.05E-04	1.41E-07	1.45E-10	0.30
rs55676236	NEK10	A/C	0.97 (0.95 - 0.98)	0.97 (0.96 - 0.98)	1.03 (0.97 - 1.11)	3.22E-05	6.58E-07	9.12E-11	0.32
rs1054020	SLC22A5	C/T	0.97 (0.96 - 0.99)	0.95 (0.93 - 0.97)	1.05 (0.95 - 1.16)	4.94E-03	1.59E-08	2.35E-09	0.33
rs62202836	N/A	C/T	0.96 (0.94 - 0.98)	0.97 (0.96 - 0.98)	1.04 (0.96 - 1.12)	4.35E-06	6.52E-05	1.82E-09	0.33
rs661204	N/A	G/A	1.06 (1.03 - 1.08)	1.06 (1.04 - 1.08)	0.95 (0.86 - 1.05)	1.02E-06	2.56E-10	1.50E-15	0.33
rs72755295	EXO1	A/G	1.17 (1.12 - 1.22)	1.07 (1.04 - 1.11)	0.91 (0.74 - 1.13)	2.32E-12	5.21E-05	5.14E-14	0.39
rs149934734	ATM	C/T	1.27 (1.17 - 1.38)	1.09 (1.05 - 1.13)	0.91 (0.74 - 1.13)	2.01E-08	2.74E-05	5.90E-10	0.40
rs35138525	N/A	C/T	1.04 (1.02 - 1.05)	1.03 (1.01 - 1.04)	1.03 (0.96 - 1.10)	2.48E-05	5.31E-05	7.78E-09	0.41
rs11599804	FGFR2	G/A	1.05 (1.04 - 1.07)	1.05 (1.03 - 1.06)	1.03 (0.96 - 1.10)	2.14E-10	6.12E-12	9.87E-21	0.43
rs4784227	CASC16	C/T	1.05 (1.03 - 1.06)	1.05 (1.04 - 1.07)	0.97 (0.90 - 1.05)	9.19E-07	6.50E-13	4.31E-18	0.45
rs62237617	CHEK2	C/T	1.74 (1.59 - 1.90)	1.67 (1.46 - 1.90)	0.73 (0.33 - 1.64)	1.06E-33	2.95E-14	3.00E-46	0.45
rs35251485	ZFXH4-AS1	G/A	0.92 (0.89 - 0.95)	0.90 (0.88 - 0.92)	0.96 (0.84 - 1.10)	3.00E-08	4.38E-15	1.26E-21	0.53
rs11263761	HNF1B	A/G	0.96 (0.94 - 0.97)	0.97 (0.96 - 0.98)	0.98 (0.92 - 1.05)	2.62E-07	1.02E-05	3.01E-11	0.57
rs162892	P4HA2	A/G	1.03 (1.01 - 1.04)	1.03 (1.02 - 1.05)	0.98 (0.91 - 1.05)	8.15E-04	4.92E-06	1.65E-08	0.58
rs188140481	N/A	T/A	1.36 (1.27 - 1.45)	1.29 (1.19 - 1.40)	0.86 (0.50 - 1.48)	3.61E-20	1.69E-09	6.18E-28	0.59
rs112381112	TANGO6	G/T	0.95 (0.93 - 0.98)	0.94 (0.92 - 0.97)	1.03 (0.9 - 1.18)	7.92E-04	8.23E-06	2.89E-08	0.67
rs12134662	PADI6	A/G	1.04 (1.02 - 1.06)	1.06 (1.05 - 1.08)	1.01 (0.95 - 1.08)	1.48E-06	1.41E-21	1.64E-25	0.70
rs11571815	BRCA2	G/A	1.18 (1.09 - 1.28)	1.18 (1.10 - 1.26)	1.07 (0.74 - 1.56)	4.57E-05	7.41E-07	1.43E-10	0.72
rs12653202	N/A	A/C	1.04 (1.02 - 1.07)	1.04 (1.02 - 1.06)	1.01 (0.92 - 1.11)	2.38E-04	1.02E-05	9.73E-09	0.83
rs55775505	CASC15	C/T	1.04 (1.02 - 1.06)	1.03 (1.02 - 1.05)	0.99 (0.93 - 1.07)	3.21E-06	1.44E-06	2.87E-11	0.85
rs113934718	ATAD5	C/A	0.98 (0.96 - 0.99)	0.97 (0.95 - 0.98)	0.99 (0.92 - 1.07)	4.35E-03	1.11E-06	2.47E-08	0.87
rs4268748	DEF8	T/C	1.06 (1.05 - 1.08)	1.07 (1.06 - 1.09)	1.00 (0.93 - 1.07)	9.56E-12	2.48E-24	2.14E-34	0.89
rs4848599	N/A	T/C	1.06 (1.03 - 1.09)	1.05 (1.03 - 1.07)	0.99 (0.90 - 1.10)	9.49E-05	3.50E-06	1.61E-09	0.91
rs1126809	TYR	G/A	1.06 (1.03 - 1.08)	1.06 (1.04 - 1.07)	1.00 (0.93 - 1.08)	1.12E-07	2.96E-16	1.95E-22	0.93
rs214793	TGM3	C/T	0.95 (0.93 - 0.97)	0.93 (0.92 - 0.95)	1.00 (0.92 - 1.09)	4.95E-06	2.00E-17	1.40E-21	0.94
rs719338	ZMIZ1	G/T	0.97 (0.96 - 0.99)	0.97 (0.96 - 0.98)	1.00 (0.94 - 1.07)	1.27E-03	2.66E-06	1.31E-08	0.95
rs62329727	N/A	T/C	1.12 (0.97 - 1.30)	1.19 (1.12 - 1.26)	1.00 (0.72 - 1.40)	1.16E-01	4.96E-09	1.85E-09	0.99
rs79134926	N/A	G/T	0.97 (0.95 - 0.99)	0.92 (0.90 - 0.94)	1.00 (0.90 - 1.11)	1.56E-03	2.66E-16	3.61E-16	1.00
rs138213197	HOBX13	C/T	1.53 (1.40 - 1.67)	1.49 (1.28 - 1.73)	N/A	6.43E-21	1.54E-07	6.14E-27	N/A
rs148874756, rs201616617	N/A	C/CTGT	0.97 (0.95 - 0.99)	0.97 (0.96 - 0.98)	N/A	3.63E-04	1.79E-05	2.47E-08	N/A
rs34138847, rs548053708	N/A	GTATT/G	1.04 (1.02 - 1.05)	1.03 (1.01 - 1.04)	N/A	2.53E-05	5.84E-05	7.97E-09	N/A
rs515726080	PALB2	A/G	3.56 (2.84 - 4.47)	N/A	N/A	6.76E-28	N/A	6.76E-28	N/A
rs533977303	RP11-962G15.1	G/C	2.70 (1.89 - 3.84)	N/A	N/A	4.51E-08	N/A	4.51E-08	N/A
rs5987402	N/A	G/T	0.97 (0.96 - 0.99)	0.98 (0.97 - 0.99)	N/A	1.04E-04	8.60E-05	3.81E-08	N/A
rs74653330	OCA2	C/T	1.15 (1.10 - 1.19)	1.17 (0.92 - 1.48)	N/A	8.88E-13	0.21	3.90E-13	N/A
rs75507031	CASP8, LS2CR12	C/T	0.95 (0.94 - 0.97)	0.92 (0.91 - 0.94)	N/A	1.46E-08	2.07E-27	9.23E-33	N/A
chr19:17104735	N/A	A/ AAAAAAAC	N/A	0.96 (0.95 - 0.98)	N/A	N/A	2.95E-08	2.95E-08	N/A
chr11:113707268	N/A	A/ATTG	N/A	1.05 (1.03 - 1.06)	N/A	N/A	7.85E-09	7.85E-09	N/A
chr5:1339775	N/A	A/G	N/A	0.95 (0.94 - 0.96)	N/A	N/A	8.58E-15	8.58E-15	N/A

Supplementary Table S10. 62 Lead SNVs from FinnGen and UKB pan-cancer analysis and their overlap with the IPF meta-analysis.

## REFERENCES

- 1 Delaneau O, Zagury J-F, Robinson MR, Marchini JL, Dermitzakis ET. Accurate, scalable and integrative haplotype estimation. *Nat Commun* 2019; **10**: 5436.
- 2 Browning BL, Browning SR. Genotype Imputation with Millions of Reference Samples. *Am J Hum Genet* 2016; **98**: 116–26.
- 3 Zekavat S.M., Lin S-L, Bick A.G., Liu A. et al. Hematopoietic mosaic chromosomal alterations and risk for infection among 767,891 individuals without blood cancer. <https://www.medrxiv.org/content/10.1101/2020.11.12.20230821v1.full.pdf>.
- 4 Thompson DJ, Genovese G, Halvardson J, et al. Genetic predisposition to mosaic Y chromosome loss in blood. *Nature* 2019; **575**: 652–7.
- 5 Machiela MJ, Zhou W, Karlins E, et al. Female chromosome X mosaicism is age-related and preferentially affects the inactivated X chromosome. *Nat Commun* 2016; **7**: 1–9.
- 6 Albrecht E, Sillanpää E, Karrasch S, et al. Telomere length in circulating leukocytes is associated with lung function and disease. *Eur Respir J* 2014; **43**: 983–92.
- 7 Broer L, Raschenberger J, Deelen J, et al. Association of adiponectin and leptin with relative telomere length in seven independent cohorts including 11,448 participants. *Eur J Epidemiol* 2014; **29**: 629–38.
- 8 Karczewski KJ, Francioli LC, Tiao G, et al. The mutational constraint spectrum quantified from variation in 141,456 humans. *Nature* 2020; **581**: 434–43.
- 9 Jiang X, Hao H-X, Growney JD, et al. Inactivating mutations of RNF43 confer Wnt dependency in pancreatic ductal adenocarcinoma. *Proc Natl Acad Sci U S A* 2013; **110**: 12649–54.
- 10 Li C, Stoma S, Lotta LA, et al. Genome-wide Association Analysis in Humans Links Nucleotide Metabolism to Leukocyte Telomere Length. *Am J Hum Genet* 2020; **106**: 389–404.
- 11 Terao C, Suzuki A, Momozawa Y, et al. Chromosomal alterations among age-related haematopoietic clones in Japan. *Nature* 2020; **584**: 130–5.
- 12 Samur MK. RTCGAToolbox: a new tool for exporting TCGA Firehose data. *PLoS One* 2014; **9**: e106397.

# Contributors of FinnGen

## Steering Committee

Aarno Palotie Institute for Molecular Medicine Finland, HiLIFE, University of Helsinki, Finland

Mark Daly Institute for Molecular Medicine Finland, HiLIFE, University of Helsinki, Finland

## Pharmaceutical companies

Bridget Riley-Gills Abbvie, Chicago, IL, United States

Howard Jacob Abbvie, Chicago, IL, United States

Dirk Paul Astra Zeneca, Cambridge, United Kingdom

Heiko Runz Biogen, Cambridge, MA, United States

Sally John Biogen, Cambridge, MA, United States

Robert Plenge Celgene, Summit, NJ, United States/Bristol Myers Squibb, New York, NY, United States

Mark McCarthy Genentech, San Francisco, CA, United States

Julie Hunkapiller Genentech, San Francisco, CA, United States

Meg Ehm GlaxoSmithKline, Brentford, United Kingdom

Kirsi Auro GlaxoSmithKline, Brentford, United Kingdom

Caroline Fox Merck, Kenilworth, NJ, United States

Anders Mälarstig Pfizer, New York, NY, United States

Katherine Klinger Sanofi, Paris, France

Deepak Raipal Sanofi, Paris, France

Tim Behrens Maze Therapeutics, San Francisco, CA, United States

Robert Yang Janssen Biotech, Beerse, Belgium

Richard Siegel Novartis, Basel, Switzerland

## University of Helsinki & Biobanks

Tomi Mäkelä HiLIFE, University of Helsinki, Finland, Finland

Jaakko Kaprio Institute for Molecular Medicine Finland, HiLIFE, Helsinki, Finland, Finland

Petri Virolainen Auria Biobank / University of Turku / Hospital District of Southwest Finland, Turku, Finland



Mengzhen Liu	Abbvie, Chicago, IL, United States
Ioanna Tachmazidou	Astra Zeneca, Cambridge, United Kingdom
Chia-Yen Chen	Biogen, Cambridge, MA, United States
Heiko Runz	Biogen, Cambridge, MA, United States
Shameek Biswas	Celgene, Summit, NJ, United States/Bristol Myers Squibb, New York, NY, United States
Julie Hunkapiller	Genentech, San Francisco, CA, United States
Meg Ehm	GlaxoSmithKline, Brentford, United Kingdom
Neha Raghavan	Merck, Kenilworth, NJ, United States
Adriana Huertas-Vazquez	Merck, Kenilworth, NJ, United States
Anders Mälarstig	Pfizer, New York, NY, United States
Xinli Hu	Pfizer, New York, NY, United States
Katherine Klinger	Sanofi, Paris, France
Matthias Gossel	Sanofi, Paris, France
Robert Graham	Maze Therapeutics, San Francisco, CA, United States
Tim Behrens	Maze Therapeutics, San Francisco, CA, United States
Beryl Cummings	Maze Therapeutics, San Francisco, CA, United States
Wilco Fleuren	Janssen Biotech, Beerse, Belgium
Dawn Waterworth	Janssen Biotech, Beerse, Belgium
Nicole Renaud	Novartis, Basel, Switzerland
Aviv Madar	Novartis, Basel, Switzerland
Maen Obeidat	Novartis, Basel, Switzerland

### **University of Helsinki & Biobanks**

Samuli Ripatti	Institute for Molecular Medicine Finland, HiLIFE, Helsinki, Finland
Johanna Schleutker	Auria Biobank / Univ. of Turku / Hospital District of Southwest Finland, Turku, Finland
Markus Perola	THL Biobank / The National Institute of Health and Welfare
Helsinki, Finland	

Mikko Arvas Finnish Red Cross Blood Service / Finnish Hematology Registry and Clinical  
Biobank, Helsinki, Finland

Olli Carpén Helsinki Biobank / Helsinki University and Hospital District of Helsinki and  
Uusimaa, Helsinki

Reetta Hinttala Northern Finland Biobank Borealis / University of Oulu / Northern  
Ostrobothnia Hospital District, Oulu, Finland

Johannes Kettunen Northern Finland Biobank Borealis / University of Oulu / Northern Ostrobothnia  
Hospital District, Oulu, Finland

Johanna Mäkelä Finnish Clinical Biobank Tampere / University of Tampere /  
Pirkanmaa Hospital District, Tampere, Finland

Arto Mannermaa Biobank of Eastern Finland / University of Eastern Finland /  
Northern Savo Hospital District, Kuopio, Finland

Jari Laukkanen Central Finland Biobank / University of Jyväskylä / Central  
Finland Health Care District, Jyväskylä, Finland

Urho Kujala Central Finland Biobank / University of Jyväskylä / Central Finland Health Care  
District, Jyväskylä, Finland

## Clinical Groups

### Neurology Group

Reetta Kälviäinen Northern Savo Hospital District, Kuopio, Finland

Valtteri Julkunen Northern Savo Hospital District, Kuopio, Finland

Hilkka Soininen Northern Savo Hospital District, Kuopio, Finland

Anne Remes Northern Ostrobothnia Hospital District, Oulu, Finland

Mikko Hiltunen Northern Savo Hospital District, Kuopio, Finland

Jukka Peltola Pirkanmaa Hospital District, Tampere, Finland

Pentti Tienari Hospital District of Helsinki and Uusimaa, Helsinki, Finland

Juha Rinne Hospital District of Southwest Finland, Turku, Finland

Roosa Kallionpää Hospital District of Southwest Finland, Turku, Finland

Ali Abbasi Abbvie, Chicago, IL, United States

Adam Ziemann Abbvie, Chicago, IL, United States



Jeffrey Waring	Abbvie, Chicago, IL, United States
Sahar Esmaeeli	Abbvie, Chicago, IL, United States
Nizar Smaoui	Abbvie, Chicago, IL, United States
Anne Lehtonen	Abbvie, Chicago, IL, United States
Susan Eaton	Biogen, Cambridge, MA, United States
Heiko Runz	Biogen, Cambridge, MA, United States
Sanni Lahdenperä	Biogen, Cambridge, MA, United States
Janet van Adelsberg	Celgene, Summit, NJ, United States/ Bristol Myers Squibb, New York, NY, United States
Shameek Biswas	Celgene, Summit, NJ, United States/ Bristol Myers Squibb, New York, NY, United States
Julie Hunkapiller	Genentech, San Francisco, CA, United States
Natalie Bowers	Genentech, San Francisco, CA, United States
Edmond Teng	Genentech, San Francisco, CA, United States
Sarah Pendergrass	Genentech, San Francisco, CA, United States
Onuralp Soylemez	Merck, Kenilworth, NJ, United States
Kari Linden	Pfizer, New York, NY, United States
Fanli Xu	GlaxoSmithKline, Brentford, United Kingdom
David Pulford	GlaxoSmithKline, Brentford, United Kingdom
Kirsi Auro	GlaxoSmithKline, Brentford, United Kingdom
Laura Addis	GlaxoSmithKline, Brentford, United Kingdom
John Eicher	GlaxoSmithKline, Brentford, United Kingdom
Minna Raivio	Hospital District of Helsinki and Uusimaa, Helsinki, Finland
Sarah Pendergrass	Genentech, San Francisco, CA, United States
Beryl Cummings	Maze Therapeutics, San Francisco, CA, United States
Juulia Partanen	Institute for Molecular Medicine Finland, HiLIFE, University of Helsinki, Finland

### **Gastroenterology Group**

Martti Färkkilä	Hospital District of Helsinki and Uusimaa, Helsinki, Finland
-----------------	--

Jukka Koskela	Hospital District of Helsinki and Uusimaa, Helsinki, Finland
Sampsa Pikkarainen	Hospital District of Helsinki and Uusimaa, Helsinki, Finland
Airi Jussila	Pirkanmaa Hospital District, Tampere, Finland
Katri Kaukinen	Pirkanmaa Hospital District, Tampere, Finland
Timo Blomster	Northern Ostrobothnia Hospital District, Oulu, Finland
Mikko Kiviniemi	Northern Savo Hospital District, Kuopio, Finland
Markku Voutilainen	Hospital District of Southwest Finland, Turku, Finland
Ali Abbasi	Abbvie, Chicago, IL, United States
Graham Heap	Abbvie, Chicago, IL, United States
Jeffrey Waring	Abbvie, Chicago, IL, United States
Nizar Smaoui	Abbvie, Chicago, IL, United States
Fedik Rahimov	Abbvie, Chicago, IL, United States
Anne Lehtonen	Abbvie, Chicago, IL, United States
Keith Usiskin	Celgene, Summit, NJ, United States/ Bristol Myers Squibb, New York, NY,
United States	
Tim Lu	Genentech, San Francisco, CA, United States
Natalie Bowers	Genentech, San Francisco, CA, United States
Danny Oh	Genentech, San Francisco, CA, United States
Sarah Pendergrass	Genentech, San Francisco, CA, United States
Kirsi Kalpala	Pfizer, New York, NY, United States
Melissa Miller	Pfizer, New York, NY, United States
Xinli Hu	Pfizer, New York, NY, United States
Linda McCarthy	GlaxoSmithKline, Brentford, United Kingdom
Onuralp Soylemez	Merck, Kenilworth, NJ, United States
Mark Daly	Institute for Molecular Medicine Finland, HiLIFE, University of Helsinki, Finland

### **Rheumatology Group**

Kari Eklund	Hospital District of Helsinki and Uusimaa, Helsinki, Finland
Antti Palomäki	Hospital District of Southwest Finland, Turku, Finland
Pia Isomäki	Pirkanmaa Hospital District, Tampere, Finland

Laura Pirilä	Hospital District of Southwest Finland, Turku, Finland
Oili Kaipainen-Seppänen	Northern Savo Hospital District, Kuopio, Finland
Johanna Huhtakangas	Northern Ostrobothnia Hospital District, Oulu, Finland
Ali Abbasi	Abbvie, Chicago, IL, United States
Jeffrey Waring	Abbvie, Chicago, IL, United States
Fedik Rahimov	Abbvie, Chicago, IL, United States
Apinya Lertratanakul	Abbvie, Chicago, IL, United States
Nizar Smaoui	Abbvie, Chicago, IL, United States
Anne Lehtonen	Abbvie, Chicago, IL, United States
David Close	Astra Zeneca, Cambridge, United Kingdom
Marla Hochfeld	Celgene, Summit, NJ, United States/ Bristol Myers Squibb, New York, NY, United States
Natalie Bowers	Genentech, San Francisco, CA, United States
Sarah Pendergrass	Genentech, San Francisco, CA, United States
Onuralp Soylemez	Merck, Kenilworth, NJ, United States
Kirsi Kalpala	Pfizer, New York, NY, United States
Nan Bing	Pfizer, New York, NY, United States
Xinli Hu	Pfizer, New York, NY, United States
Jorge Esparza Gordillo	GlaxoSmithKline, Brentford, United Kingdom
Kirsi Auro	GlaxoSmithKline, Brentford, United Kingdom
Dawn Waterworth	Janssen Biotech, Beerse, Belgium
Nina Mars	Institute for Molecular Medicine Finland, HiLIFE, Helsinki, Finland

### **Pulmonology Group**

Tarja Laitinen	Pirkanmaa Hospital District, Tampere, Finland
Margit Pelkonen	Northern Savo Hospital District, Kuopio, Finland
Paula Kauppi	Hospital District of Helsinki and Uusimaa, Helsinki, Finland
Hannu Kankaanranta	Pirkanmaa Hospital District, Tampere, Finland
Terttu Harju	Northern Ostrobothnia Hospital District, Oulu, Finland

Riitta Lahesmaa	Hospital District of Southwest Finland, Turku, Finland
Nizar Smaoui	Abbvie, Chicago, IL, United States
Alex Mackay	Astra Zeneca, Cambridge, United Kingdom
Glenda Lassi	Astra Zeneca, Cambridge, United Kingdom
Susan Eaton	Biogen, Cambridge, MA, United States
Steven Greenberg	Celgene, Summit, NJ, United States/ Bristol Myers Squibb, New York, NY, United States
Hubert Chen	Genentech, San Francisco, CA, United States
Sarah Pendergrass	Genentech, San Francisco, CA, United States
Natalie Bowers	Genentech, San Francisco, CA, United States
Joanna Betts	GlaxoSmithKline, Brentford, United Kingdom
Soumitra Ghosh	GlaxoSmithKline, Brentford, United Kingdom
Kirsi Auro	GlaxoSmithKline, Brentford, United Kingdom
Rajashree Mishra	GlaxoSmithKline, Brentford, United Kingdom
Sina Rüeger	Institute for Molecular Medicine Finland, HiLIFE, University of Helsinki, Finland

### **Cardiometabolic Diseases Group**

Teemu Niiranen	The National Institute of Health and Welfare Helsinki, Finland
Felix Vaura	The National Institute of Health and Welfare Helsinki, Finland
Veikko Salomaa	The National Institute of Health and Welfare Helsinki, Finland
Markus Juonala	Hospital District of Southwest Finland, Turku, Finland
Kaj Metsärinne	Hospital District of Southwest Finland, Turku, Finland
Mika Kähönen	Pirkanmaa Hospital District, Tampere, Finland
Juhani Juntila	Northern Ostrobothnia Hospital District, Oulu, Finland
Markku Laakso	Northern Savo Hospital District, Kuopio, Finland
Jussi Pihlajamäki	Northern Savo Hospital District, Kuopio, Finland
Daniel Gordin	Hospital District of Helsinki and Uusimaa, Helsinki, Finland
Juha Sinisalo	Hospital District of Helsinki and Uusimaa, Helsinki, Finland
Marja-Riitta Taskinen	Hospital District of Helsinki and Uusimaa, Helsinki, Finland

Tiinamaija Tuomi	Hospital District of Helsinki and Uusimaa, Helsinki, Finland
Jari Laukkanen	Central Finland Health Care District, Jyväskylä, Finland
Benjamin Challis	Astra Zeneca, Cambridge, United Kingdom
Dirk Paul	Astra Zeneca, Cambridge, United Kingdom
Julie Hunkapiller	Genentech, San Francisco, CA, United States
Natalie Bowers	Genentech, San Francisco, CA, United States
Sarah Pendergrass	Genentech, San Francisco, CA, United States
Onuralp Soylemez	Merck, Kenilworth, NJ, United States
Jaakko Parkkinen	Pfizer, New York, NY, United States
Melissa Miller	Pfizer, New York, NY, United States
Russell Miller	Pfizer, New York, NY, United States
Audrey Chu	GlaxoSmithKline, Brentford, United Kingdom
Kirsi Auro	GlaxoSmithKline, Brentford, United Kingdom
Keith Usiskin	Celgene, Summit, NJ, United States/ Bristol Myers Squibb, New York, NY, United States
Amanda Elliott	Institute for Molecular Medicine Finland, HiLIFE, University of Helsinki, Finland / Broad Institute, Cambridge, MA, United States
Joel Rämö	Institute for Molecular Medicine Finland, HiLIFE, University of Helsinki, Finland
Samuli Ripatti	Institute for Molecular Medicine Finland, HiLIFE, University of Helsinki, Finland
Mary Pat Reeve	Institute for Molecular Medicine Finland, HiLIFE, University of Helsinki, Finland
Sanni Ruotsalainen	Institute for Molecular Medicine Finland, HiLIFE, University of Helsinki, Finland

### **Oncology Group**

Tuomo Meretoja	Hospital District of Helsinki and Uusimaa, Helsinki, Finland
Heikki Joensuu	Hospital District of Helsinki and Uusimaa, Helsinki, Finland
Olli Carpén	Hospital District of Helsinki and Uusimaa, Helsinki, Finland
Lauri Aaltonen	Hospital District of Helsinki and Uusimaa, Helsinki, Finland
Johanna Mattson	Hospital District of Helsinki and Uusimaa, Helsinki, Finland
Annika Auranen	Pirkanmaa Hospital District , Tampere, Finland

Peeter Karihtala	Northern Ostrobothnia Hospital District, Oulu, Finland
Saila Kauppila	Northern Ostrobothnia Hospital District, Oulu, Finland
Päivi Auvinen	Northern Savo Hospital District, Kuopio, Finland
Klaus Elenius	Hospital District of Southwest Finland, Turku, Finland
Johanna Schleutker	Hospital District of Southwest Finland, Turku, Finland
Relja Popovic	Abbvie, Chicago, IL, United States
Jeffrey Waring	Abbvie, Chicago, IL, United States
Bridget Riley-Gillis	Abbvie, Chicago, IL, United States
Anne Lehtonen	Abbvie, Chicago, IL, United States
Jennifer Schutzman	Genentech, San Francisco, CA, United States
Julie Hunkapiller	Genentech, San Francisco, CA, United States
Natalie Bowers	Genentech, San Francisco, CA, United States
Sarah Pendergrass	Genentech, San Francisco, CA, United States
Andrey Loboda	Merck, Kenilworth, NJ, United States
Aparna Chhibber	Merck, Kenilworth, NJ, United States
Heli Lehtonen	Pfizer, New York, NY, United States
Stefan McDonough	Pfizer, New York, NY, United States
Marika Crohns	Sanofi, Paris, France
Sauli Vuoti	Sanofi, Paris, France
Diptee Kulkarni	GlaxoSmithKline, Brentford, United Kingdom
Kirsi Auro	GlaxoSmithKline, Brentford, United Kingdom
Esa Pitkänen	Institute for Molecular Medicine Finland, HiLIFE, University of Helsinki, Finland
Nina Mars	Institute for Molecular Medicine Finland, HiLIFE, University of Helsinki, Finland
Mark Daly	Institute for Molecular Medicine Finland, HiLIFE, University of Helsinki, Finland

### **Ophthalmology Group**

Kai Kaarniranta	Northern Savo Hospital District, Kuopio, Finland
Joni A Turunen	Hospital District of Helsinki and Uusimaa, Helsinki, Finland
Terhi Ollila	Hospital District of Helsinki and Uusimaa, Helsinki, Finland
Sanna Seitsonen	Hospital District of Helsinki and Uusimaa, Helsinki, Finland

Hannu Uusitalo Pirkanmaa Hospital District, Tampere, Finland  
Vesa Aaltonen Hospital District of Southwest Finland, Turku, Finland  
Hannele Uusitalo-Järvinen Pirkanmaa Hospital District, Tampere, Finland  
Marja Luodonpää Northern Ostrobothnia Hospital District, Oulu, Finland  
Nina Hautala Northern Ostrobothnia Hospital District, Oulu, Finland  
Mengzhen Liu Abbvie, Chicago, IL, United States  
Heiko Runz Biogen, Cambridge, MA, United States  
Stephanie Loomis Biogen, Cambridge, MA, United States  
Erich Strauss Genentech, San Francisco, CA, United States  
Natalie Bowers Genentech, San Francisco, CA, United States  
Hao Chen Genentech, San Francisco, CA, United States  
Sarah Pendergrass Genentech, San Francisco, CA, United States  
Anna Podgornaia Merck, Kenilworth, NJ, United States  
Juha Karjalainen Institute for Molecular Medicine Finland, HiLIFE, University of Helsinki, Finland / Broad Institute, Cambridge, MA, United States  
Esa Pitkänen Institute for Molecular Medicine Finland, HiLIFE, University of Helsinki, Finland

### **Dermatology Group**

Kaisa Tasanen Northern Ostrobothnia Hospital District, Oulu, Finland  
Laura Huilaja Northern Ostrobothnia Hospital District, Oulu, Finland  
Katariina Hannula-Jouppi Hospital District of Helsinki and Uusimaa, Helsinki, Finland  
Teea Salmi Pirkanmaa Hospital District, Tampere, Finland  
Sirkku Peltonen Hospital District of Southwest Finland, Turku, Finland  
Leena Koulu Hospital District of Southwest Finland, Turku, Finland  
Kirsi Kalpala Pfizer, New York, NY, United States  
Ying Wu Pfizer, New York, NY, United States  
David Choy Genentech, San Francisco, CA, United States  
Sarah Pendergrass Genentech, San Francisco, CA, United States  
Nizar Smaoui Abbvie, Chicago, IL, United States  
Fedik Rahimov Abbvie, Chicago, IL, United States

Anne Lehtonen Abbvie, Chicago, IL, United States

Dawn Waterworth Janssen Biotech, Beerse, Belgium

### **Odontology Group**

Pirkko Pussinen Hospital District of Helsinki and Uusimaa, Helsinki, Finland

Aino Salminen Hospital District of Helsinki and Uusimaa, Helsinki, Finland

Tuula Salo Hospital District of Helsinki and Uusimaa, Helsinki, Finland

David Rice Hospital District of Helsinki and Uusimaa, Helsinki, Finland

Pekka Nieminen Hospital District of Helsinki and Uusimaa, Helsinki, Finland

Ulla Palotie Hospital District of Helsinki and Uusimaa, Helsinki, Finland

Juha Sinisalo Hospital District of Helsinki and Uusimaa, Helsinki, Finland

Maria Siponen Northern Savo Hospital District, Kuopio, Finland

Liisa Suominen Northern Savo Hospital District, Kuopio, Finland

Päivi Mäntylä Northern Savo Hospital District, Kuopio, Finland

Ulvi Gursoy Hospital District of Southwest Finland, Turku, Finland

Vuokko Anttonen Northern Ostrobothnia Hospital District, Oulu, Finland

Kirsi Sipilä Northern Ostrobothnia Hospital District, Oulu, Finland

Sarah Pendergrass Genentech, San Francisco, CA, United States

### **Women's Health and Reproduction Group**

Hannele Laivuori Institute for Molecular Medicine Finland, HiLIFE, University of Helsinki, Finland

Venla Kurra Pirkanmaa Hospital District, Tampere, Finland

Oskari Heikinheimo Hospital District of Helsinki and Uusimaa, Helsinki, Finland

Ilkka Kalliala Hospital District of Helsinki and Uusimaa, Helsinki, Finland

Laura Kotaniemi-Talonen Pirkanmaa Hospital District, Tampere, Finland

Kari Nieminen Pirkanmaa Hospital District, Tampere, Finland

Päivi Polo Hospital District of Southwest Finland, Turku, Finland

Kaarin Mäkikallio Hospital District of Southwest Finland, Turku, Finland

Eeva Ekholm Hospital District of Southwest Finland, Turku, Finland

Marja Vääräsmäki Northern Ostrobothnia Hospital District, Oulu, Finland



Outi Uimari	Northern Ostrobothnia Hospital District, Oulu, Finland
Laure Morin-Papunen	Northern Ostrobothnia Hospital District, Oulu, Finland
Marjo Tuppurainen	Northern Savo Hospital District, Kuopio, Finland
Katja Kivinen	Institute for Molecular Medicine Finland, HiLIFE, University of Helsinki, Finland
Elisabeth Widen Helsinki, Finland	Institute for Molecular Medicine Finland, HiLIFE, University of Helsinki, Finland
Taru Tukiainen Helsinki, Finland	Institute for Molecular Medicine Finland, HiLIFE, University of Helsinki, Finland
Mary Pat Reeve Helsinki, Finland	Institute for Molecular Medicine Finland, HiLIFE, University of Helsinki, Finland
Mark Daly	Institute for Molecular Medicine Finland, HiLIFE, University of Helsinki, Finland
Liu Aoxing	Institute for Molecular Medicine Finland, HiLIFE, University of Helsinki, Finland
Eija Laakkonen	University of Jyväskylä, Jyväskylä, Finland
Niko Välimäki	University of Helsinki, Helsinki, Finland
Lauri Aaltonen	Hospital District of Helsinki and Uusimaa, Helsinki, Finland
Johannes Kettunen	Northern Ostrobothnia Hospital District, Oulu, Finland
Mikko Arvas	Finnish Red Cross Blood Service, Helsinki, Finland
Jeffrey Waring	Abbvie, Chicago, IL, United States
Bridget Riley-Gillis	Abbvie, Chicago, IL, United States
Mengzhen Liu	Abbvie, Chicago, IL, United States
Janet Kumar	GlaxoSmithKline, Brentford, United Kingdom
Kirsi Auro	GlaxoSmithKline, Brentford, United Kingdom
Andrea Ganna Helsinki, Finland	Institute for Molecular Medicine Finland, HiLIFE, University of Helsinki, Finland
Sarah Pendergrass	Genentech, San Francisco, CA, United States

### **FinnGen Analysis working group**

Justin Wade Davis	Abbvie, Chicago, IL, United States
Bridget Riley-Gillis	Abbvie, Chicago, IL, United States
Danjuma Quarless	Abbvie, Chicago, IL, United States
Fedik Rahimov	Abbvie, Chicago, IL, United States

Sahar Esmaeeli	Abbvie, Chicago, IL, United States
Slavé Petrovski	Astra Zeneca, Cambridge, United Kingdom
Eleonor Wigmore	Astra Zeneca, Cambridge, United Kingdom
Adele Mitchell	Biogen, Cambridge, MA, United States
Benjamin Sun	Biogen, Cambridge, MA, United States
Ellen Tsai	Biogen, Cambridge, MA, United States
Denis Baird	Biogen, Cambridge, MA, United States
Paola Bronson	Biogen, Cambridge, MA, United States
Ruoyu Tian	Biogen, Cambridge, MA, United States
Stephanie Loomis	Biogen, Cambridge, MA, United States
Yunfeng Huang	Biogen, Cambridge, MA, United States
Joseph Maranville	Celgene, Summit, NJ, United States/ Bristol Myers Squibb, New York, NY, United States
Shameek Biswas	Celgene, Summit, NJ, United States/ Bristol Myers Squibb, New York, NY, United States
Elmutaz Mohammed	Celgene, Summit, NJ, United States/ Bristol Myers Squibb, New York, NY, United States
Samir Wadhawan	Celgene, Summit, NJ, United States/ Bristol Myers Squibb, New York, NY, United States
Erika Kvikstad	Celgene, Summit, NJ, United States/ Bristol Myers Squibb, New York, NY, United States
Minal Caliskan	Celgene, Summit, NJ, United States/ Bristol Myers Squibb, New York, NY, United States
Diana Chang	Genentech, San Francisco, CA, United States
Julie Hunkapiller	Genentech, San Francisco, CA, United States
Tushar Bhangale	Genentech, San Francisco, CA, United States
Natalie Bowers	Genentech, San Francisco, CA, United States
Sarah Pendergrass	Genentech, San Francisco, CA, United States
Kirill Shkura	Merck, Kenilworth, NJ, United States
Victor Neduva	Merck, Kenilworth, NJ, United States

Xing Chen	Pfizer, New York, NY, United States
Åsa Hedman	Pfizer, New York, NY, United States
Karen S King	GlaxoSmithKline, Brentford, United Kingdom
Padhraig Gormley	GlaxoSmithKline, Brentford, United Kingdom
Jimmy Liu	GlaxoSmithKline, Brentford, United Kingdom
Clarence Wang	Sanofi, Paris, France
Ethan Xu	Sanofi, Paris, France
Franck Auge	Sanofi, Paris, France
Clement Chatelain	Sanofi, Paris, France
Deepak Rajpal	Sanofi, Paris, France
Dongyu Liu	Sanofi, Paris, France
Katherine Call	Sanofi, Paris, France
Tai-He Xia	Sanofi, Paris, France
Beryl Cummings	Maze Therapeutics, San Francisco, CA, United States
Matt Brauer	Maze Therapeutics, San Francisco, CA, United States
Huilei Xu	Novartis, Basel, Switzerland
Amy Cole	Novartis, Basel, Switzerland
Jonathan Chung	Novartis, Basel, Switzerland
Jaison Jacob	Novartis, Basel, Switzerland
Katrina de Lange	Novartis, Basel, Switzerland
Jonas Zierer	Novartis, Basel, Switzerland
Mitja Kurki	Institute for Molecular Medicine Finland, HiLIFE, University of Helsinki, Finland / Broad Institute, Cambridge, MA, United States
Samuli Ripatti	Institute for Molecular Medicine Finland, HiLIFE, University of Helsinki, Finland
Mark Daly	Institute for Molecular Medicine Finland, HiLIFE, University of Helsinki, Finland
Juha Karjalainen	Institute for Molecular Medicine Finland, HiLIFE, University of Helsinki, Finland / Broad Institute, Cambridge, MA, United States
Aki Havulinna	Institute for Molecular Medicine Finland, HiLIFE, University of Helsinki, Finland
Juha Mehtonen	Institute for Molecular Medicine Finland, HiLIFE, University of Helsinki, Finland

Priit Palta	Institute for Molecular Medicine Finland, HiLIFE, University of Helsinki, Finland
Shabbeer Hassan	Institute for Molecular Medicine Finland, HiLIFE, University of Helsinki, Finland
Pietro Della Briotta Parolo	Institute for Molecular Medicine Finland, HiLIFE, University of Helsinki, Finland
Wei Zhou	Broad Institute, Cambridge, MA, United States
Mutaamba Maasha	Broad Institute, Cambridge, MA, United States
Shabbeer Hassan	Institute for Molecular Medicine Finland, HiLIFE, University of Helsinki, Finland
Susanna Lemmelä	Institute for Molecular Medicine Finland, HiLIFE, University of Helsinki, Finland
Manuel Rivas	University of Stanford, Stanford, CA, United States
Aarno Palotie	Institute for Molecular Medicine Finland, HiLIFE, University of Helsinki, Finland
Arto Lehisto	Institute for Molecular Medicine Finland, HiLIFE, University of Helsinki, Finland
Andrea Ganna	Institute for Molecular Medicine Finland, HiLIFE, University of Helsinki, Finland
Vincent Llorens	Institute for Molecular Medicine Finland, HiLIFE, University of Helsinki, Finland
Hannele Laivuori	Institute for Molecular Medicine Finland, HiLIFE, University of Helsinki, Finland
Mari E Niemi	Institute for Molecular Medicine Finland, HiLIFE, University of Helsinki, Finland
Taru Tukiainen	Institute for Molecular Medicine Finland, HiLIFE, University of Helsinki, Finland
Mary Pat Reeve	Institute for Molecular Medicine Finland, HiLIFE, University of Helsinki, Finland
Henrike Heyne	Institute for Molecular Medicine Finland, HiLIFE, University of Helsinki, Finland
Nina Mars	Institute for Molecular Medicine Finland, HiLIFE, University of Helsinki, Finland
Kimmo Palin	University of Helsinki, Helsinki, Finland
Javier Garcia-Tabuenca	University of Tampere, Tampere, Finland
Harri Siirtola	University of Tampere, Tampere, Finland
Tuomo Kiiskinen	Institute for Molecular Medicine Finland, HiLIFE, University of Helsinki, Finland



Venkat Subramaniam Rathinakannan University of Turku, Turku, Finland

Nina Pitkänen Auria Biobank / University of Turku / Hospital District of Southwest Finland,  
Turku, Finland

### Biobank directors

Lila Kallio Auria Biobank / University of Turku / Hospital District of Southwest Finland,  
Turku, Finland

Sirpa Soini THL Biobank / The National Institute of Health and Welfare Helsinki, Finland

Jukka Partanen Finnish Red Cross Blood Service / Finnish Hematology Registry  
and Clinical Biobank, Helsinki, Finland

Eero Punkka Helsinki Biobank / Helsinki University and Hospital District of Helsinki and  
Uusimaa, Helsinki

Raisa Serpi Northern Finland Biobank Borealis / University of Oulu / Northern Ostrobothnia  
Hospital District, Oulu, Finland

Johanna Mäkelä Finnish Clinical Biobank Tampere / University of Tampere /  
Pirkanmaa Hospital District, Tampere, Finland

Veli-Matti Kosma Biobank of Eastern Finland / University of Eastern Finland / Northern Savo  
Hospital District, Kuopio, Finland

Teijo Kuopio Central Finland Biobank / University of Jyväskylä / Central Finland Health Care  
District, Jyväskylä, Finland

### FinnGen Teams

#### Administration

Anu Jalanko Institute for Molecular Medicine Finland, HiLIFE, University of Helsinki, Finland

Huei-Yi Shen Institute for Molecular Medicine Finland, HiLIFE, University of Helsinki, Finland

Risto Kajanne Institute for Molecular Medicine Finland, HiLIFE, University of Helsinki, Finland

Mervi Aavikko Institute for Molecular Medicine Finland, HiLIFE, University of Helsinki, Finland

#### Analysis

Mitja Kurki Institute for Molecular Medicine Finland, HiLIFE, University of Helsinki, Finland  
/ Broad Institute, Cambridge, MA, United States

Juha Karjalainen Institute for Molecular Medicine Finland, HiLIFE, University of  
Helsinki, Finland / Broad Institute, Cambridge, MA, United States

Pietro Della Briotta Parolo Institute for Molecular Medicine Finland, HiLIFE, University of Helsinki, Finland

Arto Lehisto Institute for Molecular Medicine Finland, HiLIFE, University of Helsinki, Finland

Juha Mehtonen Institute for Molecular Medicine Finland, HiLIFE, University of  
Helsinki, Finland

Wei Zhou Broad Institute, Cambridge, MA, United States

Masahiro Kanai Broad Institute, Cambridge, MA, United States

Mutaamba Maasha Broad Institute, Cambridge, MA, United States

### **Clinical Endpoint Development**

Hannele Laivuori Institute for Molecular Medicine Finland, HiLIFE, University of Helsinki, Finland

Aki Havulinna Institute for Molecular Medicine Finland, HiLIFE, University of Helsinki, Finland

Susanna Lemmelä Institute for Molecular Medicine Finland, HiLIFE, University of Helsinki, Finland

Tuomo Kiiskinen Institute for Molecular Medicine Finland, HiLIFE, University of Helsinki, Finland

L. Elisa Lahtela Institute for Molecular Medicine Finland, HiLIFE, University of  
Helsinki, Finland

Matti Peura Institute for Molecular Medicine Finland, HiLIFE, University of Helsinki, Finland

### **Communication**

Mari Kaunisto Institute for Molecular Medicine Finland, HiLIFE, University of Helsinki, Finland

### **Data Management and IT Infrastructure**

Elina Kilpeläinen Institute for Molecular Medicine Finland, HiLIFE, University of Helsinki, Finland

Timo P. Sipilä Institute for Molecular Medicine Finland, HiLIFE, University of Helsinki, Finland

Georg Brein Institute for Molecular Medicine Finland, HiLIFE, University of Helsinki, Finland

Oluwaseun A. Dada Institute for Molecular Medicine Finland, HiLIFE, University of Helsinki, Finland

Awaisa Ghazal Institute for Molecular Medicine Finland, HiLIFE, University of  
Helsinki, Finland

Anastasia Shcherban Institute for Molecular Medicine Finland, HiLIFE, University of Helsinki, Finland

### **Genotyping**

Kati Donner Institute for Molecular Medicine Finland, HiLIFE, University of Helsinki, Finland

Timo P. Sipilä Institute for Molecular Medicine Finland, HiLIFE, University of Helsinki, Finland

### **Sample Collection Coordination**

Anu Loukola Helsinki Biobank / Helsinki University and Hospital District of Helsinki and  
Uusimaa, Helsinki

### **Sample Logistics**

Päivi Laiho THL Biobank / The National Institute of Health and Welfare Helsinki, Finland

Tuuli Sistonen THL Biobank / The National Institute of Health and Welfare  
Helsinki, Finland

Essi Kaiharju THL Biobank / The National Institute of Health and Welfare Helsinki, Finland

Markku Laukkanen THL Biobank / The National Institute of Health and Welfare Helsinki, Finland

Elina Järvensivu THL Biobank / The National Institute of Health and Welfare  
Helsinki, Finland

Sini Lähteenmäki THL Biobank / The National Institute of Health and Welfare Helsinki, Finland

Lotta Männikkö THL Biobank / The National Institute of Health and Welfare  
Helsinki, Finland

Regis Wong THL Biobank / The National Institute of Health and Welfare Helsinki, Finland

### **Registry Data Operations**

Hannele Mattsson THL Biobank / The National Institute of Health and Welfare Helsinki, Finland

Kati Kristiansson THL Biobank / The National Institute of Health and Welfare Helsinki, Finland

Susanna Lemmelä Institute for Molecular Medicine Finland, HiLIFE, University of Helsinki, Finland

Sami Koskelainen THL Biobank / The National Institute of Health and Welfare Helsinki, Finland



Tero Hiekkalinna THL Biobank / The National Institute of Health and Welfare Helsinki, Finland  
Teemu Paajanen THL Biobank / The National Institute of Health and Welfare  
Helsinki, Finland

### **Sequencing Informatics**

Priit Palta Institute for Molecular Medicine Finland, HiLIFE, University of Helsinki, Finland  
Kalle Pärn Institute for Molecular Medicine Finland, HiLIFE, University of Helsinki, Finland  
Shuang Luo Institute for Molecular Medicine Finland, HiLIFE, University of Helsinki, Finland  
Vishal Sinha Institute for Molecular Medicine Finland, HiLIFE, University of Helsinki, Finland

### **Trajectory Team**

Tarja Laitinen Pirkanmaa Hospital District, Tampere, Finland  
Harri Siirtola University of Tampere, Tampere, Finland  
Javier Gracia-Tabuenca University of Tampere, Tampere, Finland  
Mika Helminen University of Tampere, Tampere, Finland  
Tiina Luukkaala University of Tampere, Tampere, Finland  
Iida Vähätalo University of Tampere, Tampere, Finland

### **Data protection officer**

Tero Jyrhämä Institute for Molecular Medicine Finland, HiLIFE, University of Helsinki, Finland

### **FinBB - Finnish biobank cooperative**

Marco Hautalahti  
Laura Mustaniemi  
Mirkka Koivusalo  
Sarah Smith  
Tom Southerington